Everfront Biotech Inc.- Rising Star in Pharmaceutical Innovation

BIO2024 Taiwan Smart Health GALA

EFB is committed to fulfilling unmet medical needs

by developing orphan drugs to treat the world’s most lethal diseases including high grade glioma and pancreatic cancer

Brain Tumor (Glioblastoma, GBM) and Pancreatic Cancer (PC)

Everfront Biotech Attend BIO 2024

BIO
2024

Cerebraca® Wafer's
Newest Clinical Trial Findings

EFB'S Mission

EFB’s Mission

EFB is committed to fulfilling unmet medical needs

Rising Star in Pharmaceutical Innovation

Rising Star in Pharmaceutical Innovation

EFB is committed to fulfilling unmet medical needs by developing orphan drugs to treat the world’s most lethal diseases.

Cerebraca® Wafer

Curing Rare Cancer

Curing Rare Cancers

Including
Glioblastoma (GBM) and
Pancreatic cancer (PC)

EF-009 | PC Treatment

PRODUCT HIGHLIGHTS of Cerebraca® Wafer

A Biodegradable Implant Targeting GBM with One-month Sustained Drug Release

Latest News

Five Teams Compete for World Championship as NSTC Leads 16 Startups to North America’s Premier Biotech Event

May 31, 2024

長弘生技贏得2023 NBRP Demo Day投資人青睞獎

Everfront Biotech Inc. Receives "Investor's Choice Award" at the 2023 NBRP Demo Day Investment Matchmaking Competition

May 5, 2023

Everfront Biotech's Investigational product, Cerebraca® Wafer, has achieved significant progress in Phase I clinical trials for the treatment of malignant brain tumors, and has been invited to speak at the Asian Congress of Neurological Surgeons (ACNS).

June 9, 2022

Everfront Biotech's Cerebraca® Wafer has Completed the Phase I - Safety Evaluation for the Treatment of Glioblastoma Multiforme, and has Initiated the Phase IIa - Efficacy Evaluation

April 9, 2022

Explore Everfront Biotech

We want to hear from you.

Development Pipeline